Shares of Prothena Corporation plc (PRTA) soared on Wednesday after Danish drugmaker Novo Nordisk (NVO) said that it expects ...

Prothena Corporation plc (NASDAQ:PRTA), announced that Novo Nordisk communicated during their second quarter 2025 earnings call on August 6, 2025 that they expect to advance coramitug, a potential ...

Shares of Prothena climbed after Novo Nordisk said during its second-quarter earnings call that it expects to advance a treatment for amyloidosis it bought from Prothena in 2021. The Dublin company's ...

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

On August 6, 2025, Prothena announced that its partner Novo Nordisk will advance coramitug, a potential first-in-class amyloid depleter antibody, into Phase 3 development for ATTR amyloidosis with ...

Prothena today reported financial results for the second quarter and first six months of 2025 and provided business highlights.

In the assessment of 12-month price targets, analysts unveil insights for Prothena Corp, presenting an average target of $34.67, a high estimate of $81.00, and a low estimate of $4.00. Observing a ...

Return on Equity (ROE): Prothena Corp's ROE falls below industry averages, indicating challenges in efficiently using equity ...

DUBLIN (AP) — DUBLIN (AP) — Prothena Corp. (PRTA) on Monday reported a loss of $125.8 million in its second quarter. The Dublin-based company said it had a loss of $2.34 per share. Losses, adjusted ...

Prothena's therapeutics for Parkinson's (Ph 2) and Alzheimer's (Ph 1) are differentiated and best-in-class antibodies. Roche and Bristol Myers have collaborations with Prothena for the Parkinson's ...

Thanks to this collaboration, Prothena could potentially end up with a total of $2.2 billion, including all funds put forth by Bristol Myers Squibb for U.S. and global rights and regulatory and ...

Prothena is a biotech with a unique, epitope targeting approach to drug development. It could earn billions in milestone payments over the next few years, and may become profitable in FY21.